Nusinersen - Wikipedia
Nusinersen, [7] marketed as Spinraza, [4] is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. [8] [4] In December 2016, it became the first approved …
Nusinersen (Spinraza®) – Spinal Muscular Atrophy (SMA)
Nusinersen, marketed in the U.S. as Spinraza ® (Biogen) is the first therapy approved for the treatment of SMA. SMA results from mutations in a gene known as SMN1, which encodes a …
Official Patient Site | SPINRAZA® (nusinersen)
SPINRAZA ® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients. Increased risk of bleeding complications has been observed …
Nusinersen (Spinraza) for Spinal Muscular Atrophy Treatment
One of the latest breakthroughs in care for patients with spinal muscular atrophy is the FDA approval of a new medicine called nusinersen (brand name Spinraza) for the treatment of …
Nusinersen injection Uses, Side Effects & Warnings - Drugs.com
Sep 12, 2024 · Nusinersen works by helping the body produce a protein essential to the function of nerves that control muscle movement. This protein is lacking in people with an inherited …
Spinraza: Uses, Dosage, Side Effects, Warnings - Drugs.com
Apr 4, 2023 · Spinraza (nusinersen) is a type of medication called an antisense oligonucleotide. It is used to treat children and adults with spinal muscular atrophy (SMA), a type of motor neuron …
FDA and EMA Accept Applications for Higher Dose Regimen of ...
Jan 23, 2025 · Nusinersen is currently commercialized under the brand name SPINRAZA in over 71 countries at the label-approved dose of 12 mg. “Continued progress to improve upon the …
Nusinersen: What is it, How does it work, How is it given - SMAUK
Nusinersen is a small piece of man-made genetic material (a synthetic antisense oligonucleotide). It targets the SMN2 gene and enables it to produce more functional, full-length SMN protein. …
Nusinersen in later-onset spinal muscular atrophy: Long-term ...
Nusinersen is an antisense oligonucleotide drug that modifies SMN2 premessenger RNA splicing, resulting in increased full-length SMN protein levels. 3 In previous clinical studies, nusinersen …
Nusinersen Treatment in Adults With Spinal Muscular Atrophy
This study provides Class IV evidence regarding nusinersen tolerability and efficacy based on reported side effects and pulmonary and physical therapy assessments in an adult SMA cohort.